469 related articles for article (PubMed ID: 24595581)
1. Biologic therapy in erythrodermic and pustular psoriasis.
Levin EC; Debbaneh M; Koo J; Liao W
J Drugs Dermatol; 2014 Mar; 13(3):342-54. PubMed ID: 24595581
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy of biologics in psoriasis: a review.
Kim IH; West CE; Kwatra SG; Feldman SR; O'Neill JL
Am J Clin Dermatol; 2012 Dec; 13(6):365-74. PubMed ID: 22967166
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
[TBL] [Abstract][Full Text] [Related]
4. Biological therapy for pustular psoriasis: a systematic review.
Falto-Aizpurua LA; Martin-Garcia RF; Carrasquillo OY; Nevares-Pomales OW; Sánchez-Flores X; Lorenzo-Rios D
Int J Dermatol; 2020 Mar; 59(3):284-296. PubMed ID: 31612467
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).
Okubo Y; Mabuchi T; Iwatsuki K; Elmaraghy H; Torisu-Itakura H; Morisaki Y; Nakajo K
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):325-332. PubMed ID: 30317671
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
Alwawi EA; Krulig E; Gordon KB
Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
[TBL] [Abstract][Full Text] [Related]
7. The status of biologic therapies in the treatment of moderate to severe psoriasis.
Menter A
Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
[TBL] [Abstract][Full Text] [Related]
8. Use of biologic agents in pediatric psoriasis.
Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
[TBL] [Abstract][Full Text] [Related]
9. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
[TBL] [Abstract][Full Text] [Related]
10. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.
Koutsoukou XA; Papadavid E; Theodoropoulos K; Rigopoulos D
Dermatol Ther; 2014; 27(5):257-9. PubMed ID: 24813816
[TBL] [Abstract][Full Text] [Related]
11. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.
Gottlieb AB; Kalb RE; Langley RG; Krueger GG; de Jong EM; Guenther L; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Menter A
J Drugs Dermatol; 2014 Dec; 13(12):1441-8. PubMed ID: 25607786
[TBL] [Abstract][Full Text] [Related]
12. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
[TBL] [Abstract][Full Text] [Related]
13. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
Sanchez IM; Sorenson E; Levin E; Liao W
Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
[TBL] [Abstract][Full Text] [Related]
14. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
15. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.
Ahn CS; Dothard EH; Garner ML; Feldman SR; Huang WW
J Am Acad Dermatol; 2015 Sep; 73(3):420-8.e1. PubMed ID: 26184440
[TBL] [Abstract][Full Text] [Related]
16. From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis.
Yip L; Harrison S; Foley P
Australas J Dermatol; 2008 Aug; 49(3):152-5. PubMed ID: 18638223
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of tumor necrosis factor-α inhibitors in psoriasis: a narrative review.
Semble AL; Davis SA; Feldman SR
Am J Clin Dermatol; 2014 Feb; 15(1):37-43. PubMed ID: 24281790
[TBL] [Abstract][Full Text] [Related]
18. Biologic Therapy in Psoriasis: Safety Profile.
Campanati A; Ganzetti G; Giuliodori K; Molinelli E; Offidani A
Curr Drug Saf; 2016; 11(1):4-11. PubMed ID: 26463245
[TBL] [Abstract][Full Text] [Related]
19. A review of clinical trials of biologic agents and small molecules for psoriasis in Asian subjects.
Tsai YC; Tsai TF
G Ital Dermatol Venereol; 2016 Aug; 151(4):412-31. PubMed ID: 26889727
[TBL] [Abstract][Full Text] [Related]
20. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
